Mario L. Suvà

The paper identifies oxidative protein states as drivers of metastatic fitness in lung cancer by linking ROS-regulated protein modifications to mitochondrial function and metastasis.

This study uses spatial transcriptomics and proteomics to analyze IDH-mutant gliomas, revealing distinct spatial organization patterns across tumor grades.

This study shows mutant IDH reprograms neural progenitor cell fate by silencing Gsx2, promoting gliomagenesis through lineage switching.

The paper identifies four immunomodulatory programs in glioma-associated myeloid cells using scRNA-seq and shows they are driven by microenvironmental cues and therapies, not cell type or mutation status.

This study shows that oncometabolite D-2HG drives enhancer hypermethylation in IDH-mutant gliomas, leading to hyporesponsive microglia and reduced immune reactivity.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

This study shows that BDNF-TrkB signaling promotes malignant synaptic plasticity in gliomas, enhancing tumor progression through mechanisms similar to long-term potentiation in the healthy brain.

The paper identifies an epigenetic neural signature in glioblastoma that correlates with poor prognosis and therapeutic vulnerability.

The paper constructs a molecular atlas of the human brain vasculature using single-cell RNA sequencing, revealing molecular heterogeneity and disease-related alterations in vascular cells.

The paper introduces scTHI, a method to identify ligand-receptor interactions in glioma using single-cell RNA sequencing data from six human datasets.

The paper develops a toolbox for scRNA-Seq and snRNA-Seq of fresh and frozen human tumors, testing it across eight tumor types and optimizing protocols for different tissue characteristics.